An agreement signed with SpectronRx, an Indiana, USA radiopharmaceutical manufacturer, designates isoSolutions as the exclusive distributor in Latin America and Canada of Spectron’s GMP grade non-carrier added (nca) Lutetium-177 radiochemical.

Non-carrier added (nca) Lutetium-177 (Lu-177) is a radioisotope used for therapeutic purposes. Therapies are being developed for the treatment of prostate cancer, kidney cancer, neuroendocrine tumors, pancreatic cancer, neuroblastomas and certain types of thyroid cancer. Demand for Lutetium-177 is growing rapidly.

SpectronRx will be working with its partner Global Morpho Pharma SAS in France to develop additional radiopharmaceutical technologies. SpectronRx also offers contract manufacturing services.

“We are excited to be working with Spectron to supply this important product to our customers, and to support development of new therapies that will ultimately benefit patients”, said David Drummond, Managing Director of isoSolutions.

About isoSolutions Marketing & Management Inc.

isoSolutions supplies a wide variety of nuclear medicine products to its key markets of Canada, the United States, Latin America and Asia. More information on the company can be found at isoSoltuions.

About SpectronRx

SpectronRx is a committed partner in molecular imaging, offering a global distribution of the most advanced radiopharmaceuticals. It offers the most reliable supply of novel research and clinical radionuclides with contract manufacturing services.

About Global Morpho Pharma SAS

Global Morpho Pharma SAS is a recently-founded French radiopharmaceutical company aiming at providing global access to high quality radionuclides for medical applications from alternative sources.